Marinus Pharmaceuticals Inc (MRNS) Return on Assets ROA from the third quarter of 2024 to third quarter of 2023 and for the year 2024, Average High and Low, Fundamental Ratios from Sep 30 2024 to Sep 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Marinus Pharmaceuticals Inc   (NASDAQ: MRNS)


Marinus Pharmaceuticals Inc 's ROA from the third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Marinus Pharmaceuticals Inc 's ROA in the third quarter of 2024?
Marinus Pharmaceuticals Inc recorded a cumulative net loss of $-140 million during 12 months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -61.64%.

However, within the Healthcare sector 859 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2024 from 4655 to 4687.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter
Y / Y Total Assets Change -68.32 % -56.72 % -39.44 % 140.33 % 8.82 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -140 -149 -145 -141 -132
Return On Assets (TTM) -61.64 % -56.91 % -49.99 % -45.16 % -59.57 %
MRNS's Total Ranking # 4687 # 4655 # 4628 # 5248 # 4598
Total Assets (TTM) in million 64 87 137 624 201
Seq. Total Assets Change -26.94 % -36.6 % -77.98 % 210.6 % -0.2 %
Seq. Net Income Change - - - - -

MRNS's 5 Years Annual ROA >> Back to MRNS Management Effectiveness >> Compare MRNS ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 406
Sector # 860
Overall # 4597

Return On Assets Statistics
High Average Low
-7.51 %
-57.73 %
-122.44 %
(Dec 31 2014)   (Sep 30 2024)





Financial Statements
Marinus Pharmaceuticals Inc 's Assets $ 64 million MRNS's Balance sheet
Marinus Pharmaceuticals Inc 's Income $ -24 million Quarterly MRNS's Income Statement
MRNS's Income by Division See MRNS's Income by Division



Annual Return On Assets (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019
Y / Y Total Assets Change 140.33 % 89.65 % -9.05 % 52.91 % 30.79 %
Total Assets in million 624 260 137 150 98
Y / Y Net Income Change - - - - -
Net Income in million -141 -20 -99 -67 -54
Annual Return On Assets -22.67 % -7.64 % -72.18 % -44.85 % -55 %

MRNS's 5 Years Annual ROA >> Back to MRNS Management Effectiveness >> Compare MRNS ROA to its Competitors



More Return On Assets Ratios
MRNS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MRNS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MRNS's Competitors
Subscribers only: Roa for Marinus Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for MRNS's Customers

You may also want to know
MRNS's Roi MRNS's Inventory Turnover Ratio MRNS's Growth Rates MRNS's Dividend Comparisons
MRNS's Profitability Ratios MRNS's Asset Turnover Ratio MRNS's Dividend Growth
MRNS's Roe MRNS's Valuation Ratios MRNS's Financial Strength Ratios MRNS's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2024, within Healthcare Sector ROA

Date modified: 2026-09-26T07:02:51+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.